Everyday Care

Check a health claim

Can rikkunshito help dyspepsia symptoms?

The claim being examined

Rikkunshito may ease fullness, early satiety, or other symptoms of functional dyspepsia (FD).

Not enough to decide

It is a treatment option for FD, but a null-primary trial and a positive selected-population trial differ. This is not evidence for stamina in healthy adults; review diagnosis, formulation, and overlapping Kampo ingredients with a clinician or pharmacist.

Checked:

A small step today

Today, gather medication and supplement photos and write one question about licorice overlap; no new medicine is required.

Who it suits: Adults with diagnosed FD discussing treatment for fullness or early satiety. A formula name alone is not a basis for treating unexplained appetite loss or seeking more stamina.

An editorial starting point. Check the main text for the studied conditions and the limits of the evidence.

Who it suits and the everyday routine

What does modern research establish?

The outcome being examined

Overall symptoms and specific fullness, early-satiety, or epigastric-pain measures in diagnosed FD, distinct from improving qi, immunity, or stamina in healthy adults.

Current assessment

The 2014 primary GPA outcome was null; DREAM found an eight-week OTE difference in selected patients. Different populations and endpoints do not yield one success rate. Read this as a clinician-assessed treatment option.

Trial · Suzuki et al., Neurogastroenterology & Motility（2014）

Randomized clinical trial: rikkunshito in the treatment of functional dyspepsia—a multicenter, double-blind, randomized, placebo-controlled study(opens in a new tab)

Findings and study population
In 247 adults with FD, 2.5 g three times daily for eight weeks did not significantly improve primary GPA response versus placebo: 33.6% versus 23.8%, p=.09. Some secondary measures, including epigastric pain, improved.
Limitations and differences from this claim
Recruitment fell short of 430 planned participants, limiting power. This was not a study of healthy adults or all indigestion. MHLW research funding and separate author industry relationships are disclosed; current products are not assumed identical.

Checked:

Trial · Tominaga et al., Neurogastroenterology & Motility（2018）

Rikkunshito simultaneously improves dyspepsia correlated with anxiety in patients with functional dyspepsia: the DREAM study(opens in a new tab)

Findings and study population
After a two-week placebo run-in, persistently symptomatic patients meeting criteria including H. pylori negativity were compared for eight weeks. The registry separates 128 safety participants from the 125-person full analysis set (FAS); the abstract reports improved eight-week OTE, p=.019.
Limitations and differences from this claim
Abstract and funding section checked; full text, dose, and product details remain unverified. Funded by the Waksman Foundation of Japan. Selected population; the 2014 dose or other products are not silently substituted.

Checked:

Trial · UMIN-CTR / UMIN000012808

DREAM study registration and final assessment(opens in a new tab)

Findings and study population
Registers OTE at weeks four and eight and reports 128 safety and 125 FAS participants. Final OTE including latest evaluable observations from discontinuers yielded p=.038; lists Waksman Foundation funding.
Limitations and differences from this claim
Keep registry final assessment distinct from the abstract’s week-eight p-value. An investigator-submitted record is neither independent replication nor an assessment of a new patient.

Checked:

Guidance · PMDA / ツムラ六君子湯エキス顆粒（医療用）

Rikkunshito medicinal product composition, precautions, and interactions(opens in a new tab)

Findings and study population
Granules containing a dry extract of eight crude drugs. Flags licorice or glycyrrhizin combinations, overlapping Kampo ingredients, and monitoring blood pressure and serum potassium.
Limitations and differences from this claim
Information for one medicinal product; it does not establish equivalence across manufacturers, extract amounts, or excipients, or stamina benefit in healthy adults.

Checked:

Connection with classical texts

Connection not established

No matching formula name was verified in the nine acquired corpora. Individual ingredients do not establish the whole formula, so no passage is attached. This does not imply absence from all historical literature.

A match in a classical text does not prove efficacy. Read historical statements separately from what modern research establishes.

What to choose in everyday life

For whom, and in which situations

Adults with diagnosed FD discussing treatment for fullness or early satiety. A formula name alone is not a basis for treating unexplained appetite loss or seeking more stamina.

Food, tea, and preparations

A multi-ingredient medicine. Prescription and nonprescription products can differ in extraction, ingredients, and excipients; granule grams and crude-herb grams differ. Do not recreate it by collecting raw herbs.

Check medicines and health conditions

  • Check other licorice-containing formulas, including shakuyakukanzoto, hochuekkito, or yokukansan. Overlap increases risk of pseudoaldosteronism and low-potassium muscle disorders.
  • Medicines containing glycyrrhizin or its salts also require caution. Include liver medicines and OTC products, not only Kampo, in the pharmacist review.

An action you can choose now

Bring the medication list and all ingredients to discuss fit with the diagnosis and treatment, including licorice overlap, review timing, and any monitoring needed.

The steps below are for the action proposed here, rather than instructions for carrying out the health claim itself.

What to prepare and check

  • A note of onset, post-meal symptoms, early satiety, and changes in weight or intake.
  • Packages or label photos of prescriptions, OTC products, Kampo, and supplements, with names and current daily amounts.

The everyday method, step by step

  1. Confirm diagnosis and purpose. If undiagnosed, report symptoms and intake changes rather than adding it for a self-defined weak stomach.
  2. Ask a pharmacist to check all products for licorice, glycyrrhizin, and other overlapping ingredients, even when brand names differ.
  3. If considered suitable, confirm product, directions, review date, and whether blood pressure or potassium monitoring is needed. Do not self-prescribe trial gram amounts.
  4. If used, follow directions and note symptoms and new problems. Do not independently prolong ineffective treatment or add another Kampo formula.

Check the modern evidence for the amounts, frequency, and duration actually studied. The short routines below are editorial starting points. They may differ from the study protocol and do not guarantee the same effects.

The shortest version today

Today, gather medication and supplement photos and write one question about licorice overlap; no new medicine is required.

Your usual routine

If use is agreed, follow the reviewed product directions and review date, recording post-meal symptoms alongside current products.

Your first week

In the first week, note symptoms, new problems, and medicine changes for the planned review. The study’s eight weeks is not a self-directed treatment course.

Alternatives for difficult days

You already use another Kampo or licorice product

Review all products with the prescriber and pharmacist before adding anything; do not adjust overlap by stopping existing medicines yourself.

Dyspepsia is undiagnosed, or intake or weight has changed

Prioritize assessment and symptom history over product choice; a constitution quiz or classical passage cannot determine FD or formula suitability.

What to notice after trying it

  • Briefly note post-meal fullness, early satiety, intake, and daily disruption separately from general stamina.
  • Check swelling, weakness, cramps, and medicine changes, and follow monitoring instructions. Absence of symptoms does not establish safe ingredient overlap.

When to stop or ask for advice

  • Stop and contact the prescriber promptly for swelling, sudden weight gain, weakness, or muscle cramps. Symptoms alone cannot determine serum potassium.
  • Serious liver injury and jaundice are listed. Disclose pregnancy, breastfeeding, and liver, kidney, or heart disease; contact care promptly for yellowing skin or eyes.

Where this method or claim is introduced, separate from evidence of benefit

When to reconsider this assessment

Update with replicated primary outcomes for defined populations and products, longer-term comparisons and safety, or verified historical formula correspondence; a classical discovery alone will not raise the efficacy judgment.

Page checked:

Examine another health claim